La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Monte Rosa Therapeutics Crescita futura
Future criteri di controllo 2/6
Monte Rosa Therapeutics is forecast to grow earnings and revenue by 26.1% and 62.5% per annum respectively. EPS is expected to grow by 34.8% per annum. Return on equity is forecast to be -117.4% in 3 years.
Informazioni chiave
26.1%
Tasso di crescita degli utili
34.8%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 30.4% |
| Tasso di crescita dei ricavi | 62.5% |
| Rendimento futuro del capitale proprio | -117.4% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 19 Aug 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
Mar 20
Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation
Sep 29Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?
May 01We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate
Jan 16We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Oct 01Monte Rosa Therapeutics rises 9% after FDA clears application for human trial of lung cancer treatment
Sep 06We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely
Jun 17We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Mar 04We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn
Sep 24Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 18 | -180 | -161 | -128 | 7 |
| 12/31/2025 | 11 | -151 | -142 | -121 | 8 |
| 12/31/2024 | 12 | -130 | -123 | -121 | 8 |
| 6/30/2024 | 6 | -130 | -68 | -61 | N/A |
| 3/31/2024 | 1 | -135 | -70 | -59 | N/A |
| 12/31/2023 | N/A | -135 | -63 | -44 | N/A |
| 9/30/2023 | N/A | -133 | -122 | -97 | N/A |
| 6/30/2023 | N/A | -125 | -118 | -93 | N/A |
| 3/31/2023 | N/A | -117 | -109 | -88 | N/A |
| 12/31/2022 | N/A | -109 | -105 | -92 | N/A |
| 9/30/2022 | N/A | -101 | -91 | -83 | N/A |
| 6/30/2022 | N/A | -94 | -89 | -80 | N/A |
| 3/31/2022 | N/A | -86 | -82 | -73 | N/A |
| 12/31/2021 | N/A | -74 | -69 | -59 | N/A |
| 9/30/2021 | N/A | -70 | -62 | -54 | N/A |
| 6/30/2021 | N/A | -57 | -50 | -43 | N/A |
| 3/31/2021 | N/A | -44 | -39 | -33 | N/A |
| 12/31/2020 | N/A | -36 | -26 | -23 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: GLUE is forecast to remain unprofitable over the next 3 years.
Guadagni vs Mercato: GLUE is forecast to remain unprofitable over the next 3 years.
Guadagni ad alta crescita: GLUE is forecast to remain unprofitable over the next 3 years.
Ricavi vs Mercato: GLUE's revenue (62.5% per year) is forecast to grow faster than the US market (8.8% per year).
Ricavi ad alta crescita: GLUE's revenue (62.5% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: GLUE is forecast to be unprofitable in 3 years.